Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFORM: Switch From Agalsidase Alfa to Agalsidase Beta in Fabry Disease
2015-000697-35Phase 4
- Sponsor
- Sanofi
- Start
- Apr 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Primary endpoint: Percent change from baseline in plasma deacylated globotriaosylceramide (lyso-GL-3).
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2015-000697-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000697-35.